Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study

[1]  K. Okumura,et al.  Use of warfarin in elderly patients with non-valvular atrial fibrillation -- subanalysis of the J-RHYTHM Registry. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[2]  K. Okumura,et al.  Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis. , 2015, Journal of cardiology.

[3]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[4]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[5]  N. Hagiwara,et al.  Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. , 2012, Thrombosis research.

[6]  K. Murasaki.  [Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009)]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[7]  Ottavio Alfieri,et al.  Corrigendum to: ‘Guidelines for the management of atrial fibrillation’ [European Heart Journal (2010) 31, 2369–2429 and EP-Europace (2010) 12, 1360–1420] , 2011 .

[8]  G. Lip.  Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. , 2011, The American journal of medicine.

[9]  K. Okumura,et al.  Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version , 2010 .

[10]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[12]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[13]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[14]  D. Singer,et al.  Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study , 2009, Circulation. Cardiovascular quality and outcomes.

[15]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[16]  A. Odén,et al.  Oral anticoagulation and risk of death: a medical record linkage study ☆ , 2003 .

[17]  Anders Odén,et al.  Oral anticoagulation and risk of death: a medical record linkage study , 2002, BMJ : British Medical Journal.

[18]  K. Minematsu,et al.  Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. , 2001, Internal medicine.

[19]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[20]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[21]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[22]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[23]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[24]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[25]  O. Miettinen,et al.  Estimability and estimation in case-referent studies. , 1976, American journal of epidemiology.

[26]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.